185 related articles for article (PubMed ID: 33676261)
1. Prevalence and factors associated with anxiety and depressive symptoms among patients hospitalized with hematological malignancies after chimeric antigen receptor T-cell (CAR-T) therapy: A cross-sectional study.
Dai H; Xu S; Han J; Li Z; Cao J; Hu T; Li H; Wei J; Dou X; Zhou F; Zheng J
J Affect Disord; 2021 May; 286():33-39. PubMed ID: 33676261
[TBL] [Abstract][Full Text] [Related]
2. Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis.
Luo W; Li C; Zhang Y; Du M; Kou H; Lu C; Mei H; Hu Y
BMC Cancer; 2022 Jan; 22(1):98. PubMed ID: 35073859
[TBL] [Abstract][Full Text] [Related]
3. Patient-Reported Symptom and Functioning Status during the First 12 Months after Chimeric Antigen Receptor T Cell Therapy for Hematologic Malignancies.
Wang XS; Srour SA; Whisenant M; Subbiah IM; Chen TH; Ponce D; Gonzalez AG; Kamal M; Mendoza T; Cleland CS; Kebriaei P; Neelapu SS; Rezvani K; Ahmed S; Shpall E
Transplant Cell Ther; 2021 Nov; 27(11):930.e1-930.e10. PubMed ID: 34265479
[TBL] [Abstract][Full Text] [Related]
4. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
[TBL] [Abstract][Full Text] [Related]
5. Perception of prognosis, quality of life, and distress in patients receiving chimeric antigen receptor T-cell therapy.
Dhawale TM; Johnson PC; Gaballa MR; Nelson AM; Lavoie MW; Boateng KY; Greydanus C; Frigault MJ; El-Jawahri A
Cancer; 2023 Feb; 129(3):441-449. PubMed ID: 36457279
[TBL] [Abstract][Full Text] [Related]
6. An international survey on the management of patients receiving CAR T-cell therapy for haematological malignancies on behalf of the Chronic Malignancies Working Party of EBMT.
Hayden PJ; Sirait T; Koster L; Snowden JA; Yakoub-Agha I
Curr Res Transl Med; 2019 Aug; 67(3):79-88. PubMed ID: 31182380
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal patient-reported outcomes in patients receiving chimeric antigen receptor T-cell therapy.
Johnson PC; Dhawale T; Newcomb RA; Amonoo HL; Lavoie MW; Vaughn D; Karpinski K; El-Jawahri A
Blood Adv; 2023 Jul; 7(14):3541-3550. PubMed ID: 36995091
[TBL] [Abstract][Full Text] [Related]
8. Exploring correlations between positive psychological resources and symptoms of psychological distress among hematological cancer patients: a cross-sectional study.
Wang ZY; Liu L; Shi M; Wang L
Psychol Health Med; 2016 Jul; 21(5):571-82. PubMed ID: 26708250
[TBL] [Abstract][Full Text] [Related]
9. Application of thromboelastography to predict the severity of bleeding after chimeric antigen receptor (CAR)-T cell therapy in patients with hematological malignancy.
Chen L; Ding S; Cheng Y; Zhou L; Yan J; Cheng Q; Jin A; Zhou X; Huang H; Hu Y
Eur J Haematol; 2024 Feb; 112(2):257-265. PubMed ID: 37698159
[TBL] [Abstract][Full Text] [Related]
10. Nutritional status alterations after chimeric antigen receptor T cell therapy in patients with hematological malignancies: a retrospective study.
Ding S; Cai L; Jin A; Zhou X; Yan J; Wang L; Zhao H; Wang T; Hu Y
Support Care Cancer; 2022 Apr; 30(4):3321-3327. PubMed ID: 34988704
[TBL] [Abstract][Full Text] [Related]
11. CAR T-Cell Therapy in Hematological Malignancies.
Haslauer T; Greil R; Zaborsky N; Geisberger R
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445701
[TBL] [Abstract][Full Text] [Related]
12. The prevalence of depressive symptoms and associated factors in countryside-dwelling older Chinese patients with hypertension.
Ma C
J Clin Nurs; 2018 Aug; 27(15-16):2933-2941. PubMed ID: 29518292
[TBL] [Abstract][Full Text] [Related]
13. Chimeric antigen receptor T cells immunotherapy: challenges and opportunities in hematological malignancies.
El-Khazragy N; Ghozy S; Emad P; Mourad M; Razza D; Farouk YK; Mohamed NA; Ahmed MK; Youssef T; Bahnasawy YM; Elmasery S
Immunotherapy; 2020 Dec; 12(18):1341-1357. PubMed ID: 33148070
[TBL] [Abstract][Full Text] [Related]
14. Gender disparities in depressive and anxiety symptoms among internal migrant workers in Shenzhen: a cross-sectional study.
Hou F; Liu H; Peng X; You L; Zhou Z; Xie H; Liu T
BMJ Open; 2020 Dec; 10(12):e041446. PubMed ID: 33268428
[TBL] [Abstract][Full Text] [Related]
15. Chimeric Antigen Receptor T Cell Exhaustion during Treatment for Hematological Malignancies.
Shen C; Zhang Z; Zhang Y
Biomed Res Int; 2020; 2020():8765028. PubMed ID: 33150182
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and predictors of anxiety and depressive symptoms among patients diagnosed with oral cancer in China: a cross-sectional study.
Yuan L; Pan B; Wang W; Wang L; Zhang X; Gao Y
BMC Psychiatry; 2020 Aug; 20(1):394. PubMed ID: 32758185
[TBL] [Abstract][Full Text] [Related]
17. Combining the best of two worlds: highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells.
Darowski D; Kobold S; Jost C; Klein C
MAbs; 2019; 11(4):621-631. PubMed ID: 30892136
[TBL] [Abstract][Full Text] [Related]
18. Adoptive therapy with CAR redirected T cells for hematological malignancies.
Li S; Yang Z; Shen J; Shan J; Qian C
Sci China Life Sci; 2016 Apr; 59(4):370-8. PubMed ID: 27009302
[TBL] [Abstract][Full Text] [Related]
19. [Chimeric antigen receptor T cell (CAR-T) therapy for refractory/relapsed hematological malignancy].
Hiramatsu H
Rinsho Ketsueki; 2018; 59(10):1948-1954. PubMed ID: 30305496
[TBL] [Abstract][Full Text] [Related]
20. [Chimeric antigen receptor T-cell therapy for hematological malignancies].
Nakazawa Y
Rinsho Ketsueki; 2019; 60(9):1351-1357. PubMed ID: 31597863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
